Transplacental immune modulation with a bacterial-derived agent protects against allergic airway inflammation

  Research In-Press Preview Cell biology Immunology Free access | 10.1172/JCI12263 

Kyle T. Mincham, Naomi M. Scott, Jean-Francois Lauzon-Joset, Jonatan Leffler, Alexander N. Larcombe, Philip A. Stumbles, Sarah A. Robertson, Christian Pasquali, Patrick G. Holt, and Deborah H. Strickland

Abstract

Chronic allergic inflammatory diseases are a major cause of morbidity, allergic asthma alone affecting over 300 million people worldwide. Epidemiological studies demonstrate that environmental stimuli are associated with either promotion or prevention of disease. Major reductions in asthma prevalence are documented in European and US farming communities. Protection is associated with exposure of mothers during pregnancy to microbial breakdown products present in farm dusts and unprocessed foods, and enhancement of innate immune competence in the children. We sought to develop a scientific rationale for progressing these findings towards clinical application for primary disease prevention. Treatment of pregnant mice with a defined clinically-approved immune-modulator was shown to markedly reduce susceptibility of their offspring to development of the hallmark clinical features of allergic airway inflammatory disease. Mechanistically, offspring displayed enhanced dendritic cell-dependent airway mucosal immune surveillance function, which resulted in more efficient generation of mucosal-homing T-regulatory cells in response to local inflammatory challenge. We provide evidence that the principal target for maternal treatment effects was the fetal dendritic cell progenitor compartment, equipping the offspring for accelerated functional maturation of the airway mucosal dendritic cell network following birth. These data provide proof-of-concept supporting the rationale for development of transplacental immune reprogramming approaches for primary disease prevention.

View PDF Adobe pdf file icon

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: Allergy, Asthma & Immunology https://t.co/bz6W0CS4gd, see more https://t.co/CpGiFv6pPL
2hreplyretweetfavorite
Interasma RT @EAACI_HQ: Are you going to #EAACI2019? Tell us what you are most looking forward to ! #EAACI #allergy #immunology #lisbon #research #…
13hreplyretweetfavorite
Interasma RT @ACAAI: Sometimes, an allergist may recommend an elimination diet to help pinpoint the food that you or your child might be sensitive to…
13hreplyretweetfavorite
Interasma RT @AllergyEaaci: Analysis of the factors associated with diagnostic skin test positivity in immediate-type hypersensitivity reactions due…
13hreplyretweetfavorite
Interasma RT @AllergyEaaci: Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with Chronic Urticaria. Corresp…
13hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma